Effects of docosahexanoic acid on Neurocognitive Impairment in HIV-infected patients: A randomized, double-blind, placebo-controlled trial

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR1900023954

Enrollment

Unknown

Registered

2019-06-19

Start date

2019-07-19

Completion date

Unknown

Last updated

2019-06-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Neurocognitive Impairment

Interventions

Experimental group:docosahexaenoic acid

control group:soybean oil

Eligibility

Sex/Gender

All

Age

18 Years to 90 Years

Inclusion criteria

Inclusion criteria: 1. male and female patients aged =18 years; 2. confirmed diagnosis of HIV-1 infection; 3. under stable cART for the prior 6 months and throughout the study period; 4. presence of neurocognitive impairment was assessed using the International HIV Dementia Scale (IHDS) and the Chinese version of Mini-Mental State Examination (MMSE).

Exclusion criteria

Exclusion criteria: 1. BMI >30kg/m2; 2. pregnancy, lactation woman; 3. with a history of diabetes mellitus, cardiovascular and cerebrovascular diseases, or serious diseases such as liver, kidney and hematopoietic system disease; 4. known intolerance to n-3 PUFA preparations; 5. consumption of high levels of alcohol (>20g/d).

Design outcomes

Primary

Measure	Time frame
Neurocognitive function;Fecal microbial genome sequencing;Fecal metabolome;	—

Countries

China

Contacts

Public ContactNa He

Fudan University

nhe@fudan.edu.cn+86 13917183273

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026